Adaptyv Bio has launched its platform to the broader scientific community, enabling users to test and synthesize designed proteins rapidly. This public launch follows a period of rapid scaling, industry validation, and an $8 million seed funding round completed earlier this year. Ace Ventures led the round, with participation from existing and new investors.
Epalinges-based Adaptyv Bio is on the mission to accelerate the design process for proteins, which today remains a long, very tedious, and expensive task as labs and companies lack the automation and data integration to perform repeatable, scalable protein testing. The startup has developed an automated wet lab for rapid experimental validation of newly designed proteins, while drastically reducing the costs per protein. Powered by artificial intelligence, this full-stack platform makes it easier for protein designers to generate data about their proteins, engineer new proteins for a variety of applications, such as designed antibodies, novel enzymes for research and industrial applications or alternative materials.
